Neuropsychiatric and Neurocognitive Manifestations in HIV-Infected Children Treated With Efavirenz in South Africa-A Retrospective Case Series

Charles K Hammond, Brian Eley, Natalia Ing, Jo M Wilmshurst, Charles K Hammond, Brian Eley, Natalia Ing, Jo M Wilmshurst

Abstract

Background: Efavirenz is associated with transient neuropsychiatric manifestations but the impact on neurocognition in children is unknown. Genetically slow metabolizers of efavirenz may be at risk of toxicity. This study describes neuropsychiatric and neurocognitive manifestations of South African children with suspected efavirenz neurotoxicity. Method: This retrospective study describes clinical features of 12 children with features consistent with efavirenz neurotoxicity between 2008 and 2014. Results: Twelve children (4 males, 8 females) aged 3-12 years (median 8.4 years) were referred to a dedicated pediatric neuroHIV service. Eight were of indigenous African (black) ancestry and 4 were of mixed ancestry. The total duration on efavirenz-containing ART at the time of referral was 6-72 (mean 31) months. Two children (both of black ancestry) were phenotypically slow metabolizers and presented with acute manifestations and high plasma efavirenz concentrations above normal range resulting in discontinuation of efavirenz. Ten other children had clinical presentations compatible with efavirenz neurotoxicity but had normal or sub-therapeutic plasma efavirenz concentrations and continued treatment with efavirenz. The acute neuropsychiatric manifestations reported included drowsiness, seizures, sleep disturbances, personality changes, ataxia, and slurred speech. These were noticed 2-8 weeks (mean 5 weeks) after commencing efavirenz and resolved over a few weeks. Nine children had neurocognitive deficits and showed poor performance in all neurocognitive domains that were tested. Interpretation: Efavirenz causes transient neuropsychiatric adverse effects and may contribute to poor long-term neurocognitive outcomes in HIV-infected children. Prospective studies comparing efavirenz-treated and efavirenz-naïve children are needed to further elucidate the manifestations of efavirenz toxicity.

Keywords: adverse effect; children; efavirenz; neurocognitive; neuropsychiatric; neurotoxicity.

References

    1. South Africa/UNAIDS Available online at: (accessed December 2, 2017)
    1. Funes HA, Apostolova N, Alegre F, Blas-Garcia A, Alvarez A, Marti-Cabrera M, et al. . Neuronal bioenergetics and acute mitochondrial dysfunction: a clue to understanding the central nervous system side effects of efavirenz. J Infect Dis. (2014) 210:1385–95. 10.1093/infdis/jiu273
    1. Decloedt EH, Maartens G. Neuronal toxicity of efavirenz: a systematic review. Exp Opin Drug Saf. (2013) 12:841–6. 10.1517/14740338.2013.823396
    1. Gaida R, Truter I, Grobler C, Kotze T, Godman B. A review of trials investigating efavirenz-induced neuropsychiatric side effects and the implications. Exp Rev Anti Infect Ther. (2016) 14:377–88. 10.1586/14787210.2016.1157469
    1. Kenedi CA, Goforth HW. A systematic review of the psychiatric side-effects of efavirenz. AIDS Behav. (2011) 15:1803–18. 10.1007/s10461-011-9939-5
    1. Ngaimisi E, Mugusi S, Minzi OM, Sasi P, Riedel K-D, Suda A, et al. . Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients. Clin Pharmacol Ther. (2010) 88:676–84. 10.1038/clpt.2010.172
    1. Ma Q, Vaida F, Wong J, Sanders CA, Kao Y, Croteau D, et al. . Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients. J Neurovirol. (2016) 22:170–8. 10.1007/s13365-015-0382-7
    1. Apostolova N, Funes HA, Blas-Garcia A, Galindo MJ, Alvarez A, Esplugues JV. Efavirenz and the CNS: what we already know and questions that need to be answered. J Antimicrob Chemother. (2015) 70:2693–708. 10.1093/jac/dkv183
    1. Funes HA, Blas-Garcia A, Esplugues JV, Apostolova N. Efavirenz alters mitochondrial respiratory function in cultured neuron and glial cell lines. J Antimicrob Chemother. (2015) 70:2249–54. 10.1093/jac/dkv098
    1. Gatch MB, Kozlenkov A, Huang R-Q, Yang W, Nguyen JD, González-Maeso J, et al. . The HIV antiretroviral drug efavirenz has LSD-like properties. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. (2013) 38:2373–84. 10.1038/npp.2013.135
    1. Naidoo P, Chetty VV, Chetty M. Impact of CYP polymorphisms, ethnicity and sex differences in metabolism on dosing strategies: the case of efavirenz. Eur J Clin Pharmacol. (2014) 70:379–89. 10.1007/s00228-013-1634-1
    1. Usach I, Melis V, Peris J-E. Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability. J Int AIDS Soc. (2013) 16:1–14. 10.7448/IAS.16.1.18567
    1. Haas DW, Ribaudo HJ, Kim RB, Tierney C, Wilkinson GR, Gulick RM, et al. . Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS Lond Engl. (2004) 18:2391–400.
    1. Cohen K, Grant A, Dandara C, McIlleron H, Pemba L, Fielding K, et al. . Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa. Antivir Ther. (2009) 14:687–95.
    1. Strehlau R, Martens L, Coovadia A, Dandara C, Norman J, Maisel J, et al. . Absence seizures associated with efavirenz initiation. Pediatr Infect Dis J. (2011) 30:1001–3. 10.1097/INF.0b013e318223b680
    1. Hauptfleisch MPK, Moore DP, Rodda JL. Efavirenz as a cause of ataxia in children. South Afr Med J Suid-Afr Tydskr Vir Geneeskd. (2015) 105:897–8. 10.7196/SAMJ.2015.v105i11.9451
    1. Pinillos F, Dandara C, Swart M, Strehlau R, Kuhn L, Patel F, et al. . Case report: Severe central nervous system manifestations associated with aberrant efavirenz metabolism in children: the role of CYP2B6 genetic variation. BMC Infect Dis. (2016) 16:56. 10.1186/s12879-016-1381-x
    1. Southern African HIV Clinicians Society Statement on the Use of Efavirenz in Children Less Than 3 Years of Age. (2013).
    1. Donald KA, Walker KG, Kilborn T, Carrara H, Langerak NG, Eley B, et al. . HIV Encephalopathy: pediatric case series description and insights from the clinic coalface. AIDS Res Ther. (2015) 12:2. 10.1186/s12981-014-0042-7
    1. Mattson SN, Roesch SC, Glass L, Deweese BN, Coles CD, Kable JA, et al. . Further development of a neurobehavioral profile of fetal alcohol spectrum disorders. Alcohol Clin Exp Res. (2013) 37:517–28. 10.1111/j.1530-0277.2012.01952.x
    1. Ferrett HL, Carey PD, Thomas KGF, Tapert SF, Fein G. Neuropsychological performance of south african treatment-naïve adolescents with alcohol dependence. Drug Alcohol Depend. (2010) 110:8–14. 10.1016/j.drugalcdep.2010.01.019
    1. Pila-Nemutandani RG, Meyer A. Behaviour planning and problem solving deficiencies in children with symptoms of attention deficit hyperactivity disorder from the Balobedu culture, Limpopo province, South Africa. J Child Adolesc Ment Health. (2016) 28:109–21. 10.2989/17280583.2016.1200582
    1. Honeth I, Laughton B, Springer PE, Cotton MF, Pretorius C. Diagnostic accuracy of the Molteno Adapted Scale for developmental delay in South African toddlers. Paediatr Int Child Health. (2019) 39:132–8. 10.1080/20469047.2018.1528754
    1. Hoare J, Fouche J-P, Phillips N, Joska JA, Paul R, Donald KA, et al. . White matter micro-structural changes in ART-naive and ART-treated children and adolescents infected with HIV in South Africa. AIDS Lond Engl. (2015) 29:1793–801. 10.1097/QAD.0000000000000766
    1. Wilmshurst JM, Hammond CK, Donald K, Hoare J, Cohen K, Eley B. NeuroAIDS in children. In: Aminoff MJ, Boller F, Swaab DF, Brew BJ, editors. Handbook of Clinical Neurology, Vol. 152, 3rd Series. The Neurology of HIV Infection. Amsterdam: Elsevier; (2018). p. 99–116. 10.1016/B978-0-444-63849-6.00008-6
    1. Wintergerst U, Hoffmann F, Jansson A, Notheis G, Huss K, Kurowski M, et al. . Antiviral efficacy, tolerability and pharmacokinetics of efavirenz in an unselected cohort of HIV-infected children. J Antimicrob Chemother. (2008) 61:1336–9. 10.1093/jac/dkn112
    1. Samia P, Petersen R, Walker KG, Eley B, Wilmshurst JM. Prevalence of seizures in children infected with human immunodeficiency virus. J Child Neurol. (2013) 28:297–302. 10.1177/0883073812446161
    1. Nijhawan AE, Zachary KC, Kwara A, Venna N. Status epilepticus resulting from severe efavirenz toxicity in an HIV-infected patient. AIDS Read. (2008) 18:386–8.
    1. McComsey G, Bhumbra N, Ma J-F, Rathore M, Alvarez A, First pediatric switch study . impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study. Pediatrics. (2003) 111:e275–81. 10.1542/peds.111.3.e275
    1. Moyle G, Fletcher C, Brown H, Mandalia S, Gazzard B. Changes in sleep quality and brain wave patterns following initiation of an efavirenz-containing triple antiretroviral regimen. HIV Med. (2006) 7:243–7. 10.1111/j.1468-1293.2006.00363.x
    1. Tukei V, Asiimwe A, Maganda A, Atugonza R, Sebuliba I, Bakeera-Kitaka S, et al. . Safety and tolerability of antiretroviral therapy among HIV-infected children and adolescents in Uganda. - PubMed - NCBI. J Acquir Immune Defic Syndr. (2012) 59:274–80. 10.1097/QAI.0b013e3182423668
    1. Mollan KR, Smurzynski M, Eron JJ, Daar ES, Campbell TB, Sax PE, et al. Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. Ann Intern Med. (2014) 161:1–10. 10.7326/M14-0293
    1. Bengtson AM, Pence BW, Mollan KR, Edwards JK, Moore RD, O'Cleirigh C, et al. . The relationship between efavirenz as initial antiretroviral therapy and suicidal thoughts among HIV-infected adults in routine care. J Acquir Immune Defic Syndr. (2017) 76:402–8. 10.1097/QAI.0000000000001510
    1. Donald KA, Hoare J, Eley B, Wilmshurst JM. Neurologic complications of pediatric human immunodeficiency virus: implications for clinical practice and management challenges in the African setting. Semin Pediatr Neurol. (2014) 21:3–11. 10.1016/j.spen.2014.01.004
    1. Wilmshurst JM, Donald KA, Eley B. Update on the key developments of the neurologic complications in children infected with HIV. Curr Opin HIV AIDS. (2014) 9:533–8. 10.1097/COH.0000000000000101

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren